XLO

Xilio Development Inc. is an innovative biotechnology firm based in Waltham, Massachusetts, focused on developing cutting-edge immunotherapies engineered to enhance the immune response in cancer patients. By leveraging its proprietary platforms, the company aims to create therapies that provide more effective and targeted treatment options, potentially improving patient outcomes in oncology. With a robust pipeline and a commitment to transforming cancer care, Xilio is well-positioned to play a significant role in the evolving landscape of cancer therapeutics.